STOCK TITAN

[Form 4] Generation Bio Co. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Generation Bio (GBIO) President & CEO and Director reported Form 4 activity on 10/15/2025. The filing shows an M transaction converting 527 restricted stock units into common shares and an F transaction disposing of 155 shares at $6.71.

Following these transactions, the reporting person directly holds 136,836 common shares and indirectly holds 22,646 and 27,500 shares via the 2018 and 2020 family trusts, respectively. Derivative holdings include 2,636 RSUs. Amounts reflect the one-for-10 reverse stock split effective July 21, 2025.

Generation Bio (GBIO) presidente e CEO e direttore ha riportato attività Form 4 il 15/10/2025. La dichiarazione mostra una transazione M che converte 527 RSU in azioni ordinarie e una transazione F che dispone di 155 azioni a $6.71. Successivamente a queste transazioni, la persona che riporta detiene direttamente 136,836 azioni ordinarie e indirettamente detiene 22,646 e 27,500 azioni tramite i trust familiari del 2018 e 2020, rispettivamente. Le partecipazioni derivanti includono 2,636 RSU. Gli importi riflettono la riduzione azionaria inversa 1-per-10 effettiva dal 21 luglio 2025.
Generation Bio (GBIO) presidente y director ejecutivo y director informó actividad Form 4 el 15/10/2025. La operación muestra una transacción M que convierte 527 RSU en acciones ordinarias y una transacción F que dispone de 155 acciones a $6.71. Después de estas transacciones, la persona reportante posee directamente 136,836 acciones ordinarias y posee indirectamente 22,646 y 27,500 acciones a través de los fideicomisos familiares de 2018 y 2020, respectivamente. Las participaciones derivadas incluyen 2,636 RSU. Las cantidades reflejan la división inversa de acciones 1-por-10 vigente desde el 21 de julio de 2025.
Generation Bio (GBIO) 사장 겸 최고경영자(CEO) 겸 이사 개인은 2025년 10월 15일 Form 4 활동을 보고했다. 신고서는 M 거래가 527 RSU를 보통주로 전환했고 F 거래가 155주를 $6.71에 처분했음을 보여준다. 이들 거래 이후, 보고자인 개인은 직접 136,836주를 보유하고 있으며 간접적으로는 각각 2018년 및 2020년 가족 신탁을 통해 22,646주와 27,500주를 보유하고 있다. 파생 보유에는 2,636 RSU가 포함된다. 금액은 일대십 역분할이 2025년 7월 21일부로 발효되었음을 반영한다.
Generation Bio (GBIO) président et PDG et administrateur a signalé une activité Form 4 le 15/10/2025. Le dépôt montre une transaction M convertissant 527 RSU en actions ordinaires et une transaction F se déchargeant de 155 actions à $6,71. À la suite de ces transactions, la personne déclarant détient directement 136,836 actions ordinaires et indirectement 22,646 et 27,500 actions via les fiduciaires familiaux de 2018 et 2020, respectivement. Les positions dérivées incluent 2,636 RSU. Les montants reflètent la réduction d'action inversée 1 pour 10 en vigueur à partir du 21 juillet 2025.
Generation Bio (GBIO) Präsidentin & CEO und Direktorin berichtete Form 4-Aktivität am 15.10.2025. Die Einreichung zeigt eine M-Transaktion, die 527 RSU in Stammaktien umwandelt, und eine F-Transaktion, die 155 Aktien zu $6,71 veräußert. Nach diesen Transaktionen hält die meldende Person direkt 136.836 Stammaktien und indirekt 22.646 und 27.500 Aktien über die Family Trusts von 2018 bzw. 2020. Derivate Bestände umfassen 2.636 RSU. Die Beträge spiegeln den 1-zu-10 Reverse-Stock-Split, der am 21. Juli 2025 wirksam wurde.
Generation Bio (GBIO) الرئيس والمدير التنفيذي والعضو أبلغ عن نشاط Form 4 في 15/10/2025. يُظهر الإبلاغ وجود صفقة M تقوم بتحويل 527 RSU إلى أسهم عادية وصفقة F تقوم بالتصرف بـ 155 سهماً بسعر $6.71. بعد هذه المعاملات، يمتلك الشخص المبلغ مباشرة 136,836 سهماً عادياً ويمتلك بشكل غير مباشر 22,646 و 27,500 سهماً عبر الثقة العائلية لعامي 2018 و2020 على التوالي. تشمل المراكز المشتقة 2,636 RSU. تعكس المبالغ تجزئة عكسية للسهم بنسبة 1 مقابل 10 سارية اعتباراً من 21 يوليو 2025.
Generation Bio (GBIO) 总裁兼首席执行官及董事于 2025/10/15 报告了 Form 4 活动。申报文件显示一笔 M 交易将 527 份受限股票单位转成普通股,以及一笔 F 交易以 $6.71 出售 155 股。 在这些交易之后,申报人直接持有 136,836 股普通股,间接持有 22,646 股和 27,500 股,分别通过 2018 年和 2020 年的家族信托。派生持股包括 2,636 RSU。金额反映自 2025 年 7 月 21 日生效的 1 对 10 的反向股票拆分
Positive
  • None.
Negative
  • None.
Generation Bio (GBIO) presidente e CEO e direttore ha riportato attività Form 4 il 15/10/2025. La dichiarazione mostra una transazione M che converte 527 RSU in azioni ordinarie e una transazione F che dispone di 155 azioni a $6.71. Successivamente a queste transazioni, la persona che riporta detiene direttamente 136,836 azioni ordinarie e indirettamente detiene 22,646 e 27,500 azioni tramite i trust familiari del 2018 e 2020, rispettivamente. Le partecipazioni derivanti includono 2,636 RSU. Gli importi riflettono la riduzione azionaria inversa 1-per-10 effettiva dal 21 luglio 2025.
Generation Bio (GBIO) presidente y director ejecutivo y director informó actividad Form 4 el 15/10/2025. La operación muestra una transacción M que convierte 527 RSU en acciones ordinarias y una transacción F que dispone de 155 acciones a $6.71. Después de estas transacciones, la persona reportante posee directamente 136,836 acciones ordinarias y posee indirectamente 22,646 y 27,500 acciones a través de los fideicomisos familiares de 2018 y 2020, respectivamente. Las participaciones derivadas incluyen 2,636 RSU. Las cantidades reflejan la división inversa de acciones 1-por-10 vigente desde el 21 de julio de 2025.
Generation Bio (GBIO) 사장 겸 최고경영자(CEO) 겸 이사 개인은 2025년 10월 15일 Form 4 활동을 보고했다. 신고서는 M 거래가 527 RSU를 보통주로 전환했고 F 거래가 155주를 $6.71에 처분했음을 보여준다. 이들 거래 이후, 보고자인 개인은 직접 136,836주를 보유하고 있으며 간접적으로는 각각 2018년 및 2020년 가족 신탁을 통해 22,646주와 27,500주를 보유하고 있다. 파생 보유에는 2,636 RSU가 포함된다. 금액은 일대십 역분할이 2025년 7월 21일부로 발효되었음을 반영한다.
Generation Bio (GBIO) président et PDG et administrateur a signalé une activité Form 4 le 15/10/2025. Le dépôt montre une transaction M convertissant 527 RSU en actions ordinaires et une transaction F se déchargeant de 155 actions à $6,71. À la suite de ces transactions, la personne déclarant détient directement 136,836 actions ordinaires et indirectement 22,646 et 27,500 actions via les fiduciaires familiaux de 2018 et 2020, respectivement. Les positions dérivées incluent 2,636 RSU. Les montants reflètent la réduction d'action inversée 1 pour 10 en vigueur à partir du 21 juillet 2025.
Generation Bio (GBIO) Präsidentin & CEO und Direktorin berichtete Form 4-Aktivität am 15.10.2025. Die Einreichung zeigt eine M-Transaktion, die 527 RSU in Stammaktien umwandelt, und eine F-Transaktion, die 155 Aktien zu $6,71 veräußert. Nach diesen Transaktionen hält die meldende Person direkt 136.836 Stammaktien und indirekt 22.646 und 27.500 Aktien über die Family Trusts von 2018 bzw. 2020. Derivate Bestände umfassen 2.636 RSU. Die Beträge spiegeln den 1-zu-10 Reverse-Stock-Split, der am 21. Juli 2025 wirksam wurde.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MCDONOUGH GEOFF

(Last) (First) (Middle)
C/O GENERATION BIO CO., 301 BINNEY ST

(Street)
CAMBRIDGE MA 02142

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Generation Bio Co. [ GBIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
PRESIDENT AND CEO
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/15/2025 M 527(1) A (2) 136,991(1) D
Common Stock 10/15/2025 F 155(1) D $6.71 136,836(1) D
Common Stock 22,646(1) I By 2018 Trust(3)
Common Stock 27,500(1) I By 2020 Trust(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (2) 10/15/2025 M 527(1) (5) (5) Common Stock 527(1) $0 2,636(1) D
Explanation of Responses:
1. Amounts reported in this Form 4 reflect the one-for-10 reverse stock split effected by the issuer on July 21, 2025.
2. Each restricted stock unit represents the right to receive one share of the company's common stock.
3. The securities are directly held by the McDonough Family 2018 Irrevocable Trust, or the 2018 Trust. The reporting person is the settlor of the 2018 Trust, Allison L. McDonough and David S. Grayzel are trustees for the 2018 Trust, and the 2018 Trust is for the benefit of Graeme and Owen McDonough. The reporting person may be deemed to beneficially own the shares of common stock owned by the 2018 Trust.
4. The securities are directly held by the McDonough Family 2020 Irrevocable Trust, or the 2020 Trust. The reporting person is the settlor of the 2020 Trust, Allison L. McDonough and David S. Grayzel are trustees for the 2020 Trust, and the 2020 Trust is for the benefit of Allison, Graeme and Owen McDonough. The reporting person may be deemed to beneficially own the shares of common stock owned by the 2020 Trust.
5. On January 20, 2023, the reporting person was granted 8,437 restricted stock units. The shares underlying the restricted stock units vest over four years, with 25% of the shares vested on January 15, 2024 and the remaining shares vesting in equal quarterly installments thereafter.
/s/ Shawna-Gay White, Attorney-in-Fact 10/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Generation Bio Co.

NASDAQ:GBIO

GBIO Rankings

GBIO Latest News

GBIO Latest SEC Filings

GBIO Stock Data

44.72M
5.77M
14.24%
62.31%
2.9%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE